Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04834024
Status:
RECRUITING
Last Update Posted:
2023-10-23
First Post:
2021-04-05
Brief Title:
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Sponsor:
Beijing Mabworks Biotech Co Ltd
Organization:
Beijing Mabworks Biotech Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-02
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-03
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-05
First Submit QC Date:
April 5 2021
Study First Post Date:
2021-04-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-19
Last Update Post Date:
2023-10-23
Last Update Post Date Type:
ACTUAL